Three Synthetic Biology Companies You’ve Never Heard of

Investors looking for opportunities with bright long-term prospects are getting interested in synthetic biology companies, which have also drawn attention from the likes of Bill Gates and Cathie Wood. What are the best synthetic biology stocks to buy now?

Many investors rushed into cannabis stocks and cryptocurrencies but were disappointed. The main problem was that they hadn't assessed their investments properly. So, before you invest in synthetic biology stocks, you should understand what the business is about.

Synthetic biology involves reprogramming the genetic structure of microbes or cells for useful results. It’s called synthetic because the outcome is a version of a natural organism with new or enhanced capabilities. Examples of synthetic biology would be redesigning the DNA of yeast to enable it to produce a particular oil that can otherwise only be extracted from a plant, or engineering a fungus to produce a vitamin that's in short supply.

Microbes could also be reengineered to remove pollutants from the air, water, or soil. Synthetic biology companies are solving major problems in medicine, agriculture, manufacturing, in addition to fighting climate change.

The future looks promising for synthetic biology companies as the application of their solutions expand. The global synthetic biology market is forecast to grow from an estimated $13.9 billion in 2022 to more than $100 billion in 2030.

In an emerging industry like synthetic biology, you can expect both winners and losers. Your best bet are companies likely to dominate. Based on that, some of the best synthetic biology companies to invest in are the following:

• Codexis (CDXS).
• Ginkgo Bioworks (DNA).
• Amyris (AMRS).

California-based Codexis was founded in 2002. The company’s work has focused on developing synthetic enzymes for food, pharmaceutical, and other life-science areas. Its partners include Nestlé Health Sciences and drug giant Takeda.

Boston-based Ginkgo Bioworks, founded in 2009, has focused on reprogramming the DNA of bacteria and other microbes so they can be more useful for food, medicine, or agricultural production. Ginkgo went public through a SPAC deal that also included Bill Gates and Cathie Wood. The company makes money through royalty arrangements with companies that apply its technology. Its clients include Bayer and Roche. Ginkgo also helped Moderna develop its COVID-19 vaccine.

California-based Amyris, founded in 2003, reengineers yeast and other microbes to enable them to convert things like sugarcane into vital ingredients for the food, pharmaceutical, beauty industries. For example, it has developed a synthetic ingredient for cosmetic products that was previously obtained from sharks, saving millions of the animals per year.